|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAD51AP1 |
Gene summary for RAD51AP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAD51AP1 | Gene ID | 10635 |
| Gene name | RAD51 associated protein 1 | |
| Gene Alias | PIR51 | |
| Cytomap | 12p13.32 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q96B01 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10635 | RAD51AP1 | P130T-E | Human | Esophagus | ESCC | 4.19e-25 | 7.69e-01 | 0.1676 |
| 10635 | RAD51AP1 | C04 | Human | Oral cavity | OSCC | 6.19e-15 | 7.99e-01 | 0.2633 |
| 10635 | RAD51AP1 | C21 | Human | Oral cavity | OSCC | 5.01e-16 | 6.10e-01 | 0.2678 |
| 10635 | RAD51AP1 | C30 | Human | Oral cavity | OSCC | 6.35e-19 | 1.27e+00 | 0.3055 |
| 10635 | RAD51AP1 | C38 | Human | Oral cavity | OSCC | 6.57e-09 | 1.09e+00 | 0.172 |
| 10635 | RAD51AP1 | C43 | Human | Oral cavity | OSCC | 4.26e-17 | 3.94e-01 | 0.1704 |
| 10635 | RAD51AP1 | C46 | Human | Oral cavity | OSCC | 6.22e-17 | 4.34e-01 | 0.1673 |
| 10635 | RAD51AP1 | C51 | Human | Oral cavity | OSCC | 1.85e-03 | 3.74e-01 | 0.2674 |
| 10635 | RAD51AP1 | C57 | Human | Oral cavity | OSCC | 3.20e-11 | 4.31e-01 | 0.1679 |
| 10635 | RAD51AP1 | C06 | Human | Oral cavity | OSCC | 3.90e-04 | 1.99e+00 | 0.2699 |
| 10635 | RAD51AP1 | C08 | Human | Oral cavity | OSCC | 1.73e-10 | 3.57e-01 | 0.1919 |
| 10635 | RAD51AP1 | LN22 | Human | Oral cavity | OSCC | 8.64e-05 | 5.98e-01 | 0.1733 |
| 10635 | RAD51AP1 | LN46 | Human | Oral cavity | OSCC | 4.44e-15 | 5.28e-01 | 0.1666 |
| 10635 | RAD51AP1 | SYSMH2 | Human | Oral cavity | OSCC | 2.35e-05 | 3.57e-01 | 0.2326 |
| 10635 | RAD51AP1 | SYSMH3 | Human | Oral cavity | OSCC | 6.44e-11 | 5.21e-01 | 0.2442 |
| 10635 | RAD51AP1 | SYSMH5 | Human | Oral cavity | OSCC | 2.68e-10 | 3.75e-01 | 0.0647 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:005105417 | Esophagus | ESCC | positive regulation of DNA metabolic process | 139/8552 | 201/18723 | 1.20e-11 | 4.33e-10 | 139 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:2001020110 | Esophagus | ESCC | regulation of response to DNA damage stimulus | 145/8552 | 219/18723 | 5.97e-10 | 1.50e-08 | 145 |
| GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:007147816 | Esophagus | ESCC | cellular response to radiation | 122/8552 | 186/18723 | 3.07e-08 | 5.73e-07 | 122 |
| GO:0071479110 | Esophagus | ESCC | cellular response to ionizing radiation | 54/8552 | 72/18723 | 3.85e-07 | 5.32e-06 | 54 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:00517831 | Esophagus | ESCC | regulation of nuclear division | 90/8552 | 139/18723 | 4.30e-06 | 4.60e-05 | 90 |
| GO:00900689 | Esophagus | ESCC | positive regulation of cell cycle process | 142/8552 | 236/18723 | 4.79e-06 | 5.08e-05 | 142 |
| GO:20010228 | Esophagus | ESCC | positive regulation of response to DNA damage stimulus | 69/8552 | 105/18723 | 2.66e-05 | 2.22e-04 | 69 |
| GO:00062826 | Esophagus | ESCC | regulation of DNA repair | 82/8552 | 130/18723 | 4.65e-05 | 3.66e-04 | 82 |
| GO:00457395 | Esophagus | ESCC | positive regulation of DNA repair | 49/8552 | 73/18723 | 1.74e-04 | 1.14e-03 | 49 |
| GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
| GO:20007793 | Esophagus | ESCC | regulation of double-strand break repair | 52/8552 | 85/18723 | 2.86e-03 | 1.21e-02 | 52 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAD51AP1 | SNV | Missense_Mutation | c.685N>T | p.Val229Phe | p.V229F | Q96B01 | protein_coding | tolerated(0.17) | possibly_damaging(0.775) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| RAD51AP1 | SNV | Missense_Mutation | novel | c.1003N>T | p.Gly335Cys | p.G335C | Q96B01 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| RAD51AP1 | SNV | Missense_Mutation | c.163N>G | p.Leu55Val | p.L55V | Q96B01 | protein_coding | tolerated(0.47) | benign(0.003) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAD51AP1 | SNV | Missense_Mutation | novel | c.938N>A | p.Ser313Asn | p.S313N | Q96B01 | protein_coding | deleterious(0.04) | benign(0.021) | TCGA-DS-A3LQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| RAD51AP1 | SNV | Missense_Mutation | novel | c.428C>G | p.Ser143Cys | p.S143C | Q96B01 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RAD51AP1 | SNV | Missense_Mutation | c.407N>C | p.Met136Thr | p.M136T | Q96B01 | protein_coding | tolerated(0.4) | benign(0.001) | TCGA-JX-A3Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAD51AP1 | SNV | Missense_Mutation | rs766644662 | c.779N>T | p.Ser260Leu | p.S260L | Q96B01 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RAD51AP1 | SNV | Missense_Mutation | c.862N>G | p.Lys288Glu | p.K288E | Q96B01 | protein_coding | deleterious(0.03) | possibly_damaging(0.71) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| RAD51AP1 | SNV | Missense_Mutation | rs766644662 | c.779N>T | p.Ser260Leu | p.S260L | Q96B01 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| RAD51AP1 | SNV | Missense_Mutation | c.839N>A | p.Ser280Tyr | p.S280Y | Q96B01 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |